Recent years have witnessed groundbreaking developments in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://owainlanl708125.mdkblog.com/45028024/novel-therapeutic-targets-in-diabetes-retatrutide-and-trizepatide